A guide to rational dosing of monoclonal antibodies

Clinical Pharmacokinetics

Volumn 51, Issue 2, 2012, Pages 119-135

  Bai, Shuang ^a   Jorga, Karin ^a,b   Xin, Yan ^a   Jin, Denise ^a   Zheng, Yanan ^a   Damico Beyer, Lisa A ^a   Gupta, Manish ^a   Tang, Meina ^a   Allison, David E ^a   Lu, Dan ^a   Zhang, Yi ^a   Joshi, Amita ^a   Dresser, Mark J ^a  

^a GENENTECH INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Dose prediction; Monoclonal antibodies; Pharmacokinetics; Pharmacology

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RITUXIMAB; TOCILIZUMAB; TRASTUZUMAB; USTEKINUMAB;

AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; BREAST CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; NONHODGKIN LYMPHOMA; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STEADY STATE;

ADULT; ANTIBODIES, MONOCLONAL; BODY SURFACE AREA; BODY WEIGHT; COMPUTER SIMULATION; DATABASES, FACTUAL; DECISION TREES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

EID: 84862962633     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11596370-000000000-00000     Document Type: Article

References (45)

1. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010 Oct 1; 49 (10): 633-59
2. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010 Feb 1; 24 (1): 23-39
3. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996 Sep; 14 (9): 2590-611 (Pubitemid 26300128)
4. Mathijssen RH, de Jong FA, Loos WJ, et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007 Aug; 12 (8): 913-23 (Pubitemid 47359133)
5. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 2010 Jul; 50 (7): 754-66
6. Arzerra (ofatumumab) injection for intravenous infusion: US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us- arzerra.pdf [Accessed 2011 Dec 7]
7. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008 Oct; 62 (5): 779-86
8. Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokineticspharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007 Sep; 64 (3): 278-91 (Pubitemid 47283867)
9. Dirks NL, Nolting A, Kovar A, et al. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 2008 Mar; 48 (3): 267-78 (Pubitemid 351257778)
10. Fukushima Y, Charoin J-E, Brewster M, et al. Population pharmacokinetic analysis of trastuzumab (Herceptin̈) based on three different dosing regimens [abstract no. 1121]. Sixteenth Meeting, Population Approach Group in Europe; 2007 Jun 13-15; Copenhagen [online]. Available from URL: http://www.page-meeting.org/default.asp?abstract=1121 [Accessed 2011 Dec 7]
11. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factoralpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003 Jun; 25 (6): 1700-21 (Pubitemid 36801943)
12. Ilaris(canakinumab): US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ilaris-ppi.pdf [Accessed 2011 Dec 7]
13. Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001 Nov; 41 (11): 1206-14 (Pubitemid 32983219)
14. Sun YN, Lu JF, Joshi A, et al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 2005 Apr; 45 (4): 468-76 (Pubitemid 40490420)
15. Cox DS, Kleiman NS, Boyle DA, et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol 2004 Sep; 44 (9): 981-90 (Pubitemid 39096813)
16. Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008 Jun; 48 (6): 681-95 (Pubitemid 351713154)
17. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an antitumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 2009 Sep; 49 (9): 1056-70
18. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007 Mar; 47 (3): 383-96 (Pubitemid 46294717)
19. Kovarik JM, Nashan B, Neuhaus P, et al. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 2001 Apr; 69 (4): 201-9 (Pubitemid 32382502)
20. Soliris(eculizumab): US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/125166lbl. pdf [Accessed 2011 Dec 7]
21. ZhuY,HuC,LuM, et al. Population pharmacokineticmodeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009 Feb; 49 (2): 162-75
22. Synagis(palivizumab) for intramuscular administration: US prescribing information [online]. Available from URL: http://www.medimmune.com/pdf/products/ synagis-pi.pdf [Accessed 2011 Dec 7]
23. Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag 2007 Jun; 3 (2): 259-68 (Pubitemid 46881453)
24. Ma P, Yang BB, Wang YM, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 2009 Oct; 49 (10): 1142-56
25. Hayashi N, Tsukamoto Y, Sallas WM, et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007 May; 63 (5): 548-61 (Pubitemid 46632569)
26. Clinical pharmacology review of BLA 97-0736 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/How DrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologic Applications/ucm113472.pdf [Accessed 2011 Dec 7]
27. Fang AF, Palmer JN, Chiu AG, et al. Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis. Int J Antimicrob Agents 2009 Jul; 34 (1): 67-71
28. Vollmer T, Blight AR, Henney 3rd HR, et al. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther 2009 Oct; 31 (10): 2215-23
29. Deng R, Iyer S, Theil FP, et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011 Jan-Feb; 3 (1): 61-6
30. Mahmood I. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 2009 Oct; 98 (10): 3850-61
31. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002 Jan; 8 (1): 221-32 (Pubitemid 34101482)
32. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001 Dec; 28 (6): 507-32 (Pubitemid 34289541)
33. Shi R, Li C, Zhang S, et al. Fixed dosing versus body size-based dosing of therapeutic proteins and peptides in adults [abstract]. 111th Annual Meeting, American Society for Clinical Pharmacology and Therapeutics; 2010 Mar 17-20; Atlanta (GA)
34. Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006 Jun; 23 (6): 1275-84 (Pubitemid 43946149)
35. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002 Dec 18; 94 (24): 1883-8 (Pubitemid 36104633)
36. Wang DD, Zhang S, Zhao H, et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009 Sep; 49 (9): 1012-24
37. Brainard J, Burmaster DE. Bivariate distributions for height and weight of men and women in the United States. Risk Anal 1992 Jun; 12 (2): 267-75
38. Gibaldi M, Perrier D, editors. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982
39. XinY, XuL, Bai S, et al. Fixeddosing evaluation of pertuzumab in cancer patients from phase I and II studies [abstract]. 111th Annual Meeting, American Society for Clinical Pharmacology and Therapeutics; 2010 Mar 17-20; Atlanta (GA)
40. Gupta M, Lorusso PM, Wang B, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. Epub 2011 Sep 27
41. Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 2010 Aug; 37 (4): 323-46
42. Krippendorff BF, Kuester K, Kloft C, et al. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn 2009 Jun; 36 (3): 239-60
43. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987 Oct 22; 317 (17): 1098
44. European Medicines Agency. ICH topic E 11: clinical investigation of medicinal products in the paediatric population [document reference CPMP/ICH/2711/99]. London: European Medicines Agency, 2001 Jan [online]. Available from URL: http://www.emea.europa.eu/docs/enGB/document-library/ Scientific-guideline/2009/09/WC500002926.pdf [Accessed 2011 Dec 7]
45. US Food and Drug Administration [FDA]. Guidance for industry: E11 clinical investigation of medicinal products in the pediatric population. Rockville (MD): FDA, 2000 Dec [online]. Available from URL: http://www.fda.gov/ downloads/RegulatoryInformation/Guidances/ucm129477.pdf [Accessed 2011 Dec 7]